コンテンツへスキップ
Merck

HNDG1MAG-36K

Millipore

MILLIPLEX® Human Neurodegenerative Disease Magnetic Bead Panel 1 - Neuroscience Multiplex Assay

The analytes available for this multiplex kit are: α2-Macroglobulin, Apo Al, Apo CIII, Apo E, Complement C3 and Complement Factor H.

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12161503
eCl@ss:
32161000
NACRES:
NA.84

品質水準

化学種の反応性

human

メーカー/製品名

Milliplex®

assay range

accuracy: 105%
(Complement Factor H)

accuracy: 110%
(Apo E)

accuracy: 75%
(Complement C3)

intra-assay cv: <10
standard curve range: 0.01-40 ng/mL
(Apo CIII)

standard curve range: 0.05-200 ng/mL
(Apo E, Complement C3)

standard curve range: 0.3-1,000 ng/mL
(Complement Factor H)

standard curve range: 0.5-2,000 ng/mL
(α-2-Macroglobulin)

standard curve range: 0.7-3,000 ng/mL
(Apo A1)

テクニック

multiplexing: suitable

検出方法

fluorometric (Luminex xMAP)

輸送温度

wet ice

詳細

Neurodegenerative disease is a condition characterized by the deterioration of neurons or their myelin sheath over time in the brain and/or spinal cord. These neurons are responsible for such everyday activities as processing sensory information, making decisions, and controlling movement. Because these cells are not easily regenerated, excessive cumulative damage can lead to age-related diseases such as Alzheimer′s and Parkinson′s disease, as well as other conditions such as amyotrophic lateral sclerosis (ALS) and epilepsy. These disorders are devastating and expensive, both on a personal and global level, and as population demographics continue to change, a therapeutic solution is critical. Consequently, research is underway to identify biomarkers that will help scientists not only understand the pathogenesis of neurodegenerative disease, but also identify people with these disorders before the onset of symptoms and potentially provide new therapeutic tools.
The “MILLIPLEX” Human Neurodegenerative Bead Panel 1 (HNDG1MAG-36K) is to be used for the simultaneous quantification of the following 7 analytes in any combination: α-2-Macroglobulin, Apo A1, Apo CIII, Apo E, Complement C3 and Complement Factor H. This kit may be used for the analysis of all above analytes in human serum, plasma, and cerebrospinal fluid samples.

Panel Type: Neuroscience

特異性

Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

アプリケーション

  • Analytes: : α2-Macroglobulin, Apo Al, Apo CIII, Apo E, Complement C3, Complement Factor H
  • Recommended Sample type: serum, plasma and CSF
  • Recommended Sample dilution: 1:40,000 diluted serum/plasma or 1:400 diluted CSF per well
  • Assay Run Time: One day
  • Research Category: Neuroscience

特徴および利点

Design your multiplex kit by choosing available analytes within this panel.

包装

Everything you need in a single kit.

保管および安定性

Recommended storage for kit components is 2 - 8°C.

その他情報

Sensitivity: See protocol for sensitivities of individual analytes

法的情報

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

ピクトグラム

Health hazardCorrosionExclamation markEnvironment

シグナルワード

Danger

危険有害性の分類

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

ターゲットの組織

Respiratory Tract

保管分類コード

10 - Combustible liquids


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

HNDG1MAG-36K-03:
HNDG1MAG-36K-02:
HNDG1MAG-36K:
HNDG1MAG-36K-06:
HNDG1MAG-36K-01:
HNDG1MAG-36K-04:
HNDG1MAG-36K-05:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis.
Mook-Kanamori, BB; Brouwer, MC; Geldhoff, M; Ende, Av; van de Beek, D
The Journal of Infection null
William T Hu et al.
Acta neuropathologica communications, 4, 14-14 (2016-02-19)
CSF levels of established Alzheimer's disease (AD) biomarkers remain stable despite disease progression, and non-amyloid non-tau biomarkers have the potential of informing disease stage and progression. We previously identified complement 3 (C3) to be decreased in AD dementia, but this
Abdul Hye et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 10(6), 799-807 (2014-07-12)
The study aimed to validate previously discovered plasma biomarkers associated with AD, using a design based on imaging measures as surrogate for disease severity and assess their prognostic value in predicting conversion to dementia. Three multicenter cohorts of cognitively healthy

関連コンテンツ

Learn how multiplex detection of Alzheimer’s disease biomarkers, using the MILLIPLEX®Human Amyloid Beta and Tau Magnetic Bead Panel, allows for a different perspective on neurodegenerative disease research.

Neuroscience multiplex assays, such as MILLIPLEX® multiplex assays, enable simultaneous measurement of neuroscience-related biomarkers to gain a better picture of neurodegenerative diseases, neurological disorders, and neuropeptide/neurohormone signaling.

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)